Arpit Vyas

Jump to

Price erosion won't impact generic cos in US: Dishman Pharma

Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh & Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals & Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang Institutional Equities.
Margins to pick up in H2, will meet FY15 guidance: Dishman

Dishman Pharma‘s margins were down due to stock building but they are expected to pick up in the second half of this fiscal, says company MD Arpit Vyas.
Margins to scale up to 20% by FY15-end: Dishman Pharma

The company is now concentrating on high margins and high value business and expects a sizable improvement by the end of the year.
Expect to cut debt by Rs 70-80 cr this year: Dishman Pharma

Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Arpit Vyas

Price erosion won't impact generic cos in US: Dishman Pharma

Margins to pick up in H2, will meet FY15 guidance: Dishman

Margins to scale up to 20% by FY15-end: Dishman Pharma

Expect to cut debt by Rs 70-80 cr this year: Dishman Pharma